Amy Suchita Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amy Suchita Patel has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Abigail Fraser
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
1 shared publicationAhmed Hassan
Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
1 shared publicationAmy Howell
Academic Women’s Health Unit, Translational Health Sciences, University of Bristol, Bristol, United Kingdom
1 shared publication- Anna Davies
Academic Women’s Health Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
1 shared publication Christy Burden
Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
1 shared publication- Danya Bakhbakhi
University of Bristol, Bristol, UK
1 shared publication
Latest Publications
- Open Access
- 26 February 2026
- Published by Wiley
Luteal phase progesterone to prevent recurrent miscarriage and improve live birth: A systematic review
Objective: Preventing recurrent miscarriage is a top research priority, for which luteal phase progesterone is a potential treatment. A systematic review was conducted to investigate the available evidence on luteal phase progesterone supplementation to reduce miscarriage, increase live birth rate and improve pregnancy outcomes in women and birthing people with a history of unexplained recurrent miscarriage. Evidence review: Pubmed, Cochrane Library, Ovid MEDLINE, Ovid EMBASE, CINAHL and ClinicalTrials.gov were systematically searched in 05/2025 to identify English-language, peer-reviewed, randomised-controlled trials and observational studies involving human participants published from the year 2000 onwards. This study adhered to PRISMA guidelines. Participants had a history of unexplained recurrent miscarriage who were prescribed luteal phase progesterone or placebo/usual care. Primary outcomes were miscarriage and live birth. Additional outcomes were informed by the miscarriage prevention core outcome set. Two independent reviewers conducted screening and study selection. Our protocol was pre-registered (PROSPERO CRD:420250653486). Results: A systematic search yielded 6722 studies. None of the 47 articles that underwent full text review met eligibility criteria. Three observational studies were identified however, due to differences in population characteristics or study design, none were eligible for inclusion. This highlights a significant gap in evidence. Conclusion: No evidence was identified linking luteal phase progesterone treatment to a reduction in miscarriage or increase in live births in women and birthing people with a history of unexplained recurrent miscarriage. A feasibility trial investigating treatment acceptability and adherence is proposed. This will subsequently support a definitive trial assessing clinical effectiveness, providing high quality evidence on luteal progesterone supplementation in recurrent miscarriage care.
- 26 February 2026
- Published by Wiley
Open AccessLuteal phase progesterone to prevent recurrent miscarriage and improve live birth: A systematic review
Objective: Preventing recurrent miscarriage is a top research priority, for which luteal phase progesterone is a potential treatment. A systematic review was conducted to investigate the available evidence on luteal phase progesterone supplementation to reduce miscarriage, increase live birth rate and improve pregnancy outcomes in women and birthing people with a history of unexplained recurrent miscarriage. Evidence review: Pubmed, Cochrane Library, Ovid MEDLINE, Ovid EMBASE, CINAHL and ClinicalTrials.gov were systematically searched in 05/2025 to identify English-language, peer-reviewed, randomised-controlled trials and observational studies involving human participants published from the year 2000 onwards. This study adhered to PRISMA guidelines. Participants had a history of unexplained recurrent miscarriage who were prescribed luteal phase progesterone or placebo/usual care. Primary outcomes were miscarriage and live birth. Additional outcomes were informed by the miscarriage prevention core outcome set. Two independent reviewers conducted screening and study selection. Our protocol was pre-registered (PROSPERO CRD:420250653486). Results: A systematic search yielded 6722 studies. None of the 47 articles that underwent full text review met eligibility criteria. Three observational studies were identified however, due to differences in population characteristics or study design, none were eligible for inclusion. This highlights a significant gap in evidence. Conclusion: No evidence was identified linking luteal phase progesterone treatment to a reduction in miscarriage or increase in live births in women and birthing people with a history of unexplained recurrent miscarriage. A feasibility trial investigating treatment acceptability and adherence is proposed. This will subsequently support a definitive trial assessing clinical effectiveness, providing high quality evidence on luteal progesterone supplementation in recurrent miscarriage care.
- Open Access
- 11 July 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (3) , e000185
Cervical screening programme accessibility for healthcare staff: ‘a call to action!’
The National Health Service (NHS) cervical screening programme has significantly reduced the incidence and mortality of cervical cancer. However, this vital service may not reach the whole eligible population. The national coverage remains below the 80% target, with only 68.7% of eligible people screened in 2023 in England. 1 Practical, psychological and socioeconomic barriers, alongside low perceived risk, continue to limit uptake.2–4 NHS statistics reported there were 1.16 million females employed in December 2024,5 the majority of whom are eligible for cervical screening. Shift work, rota inflexibility and staff shortages are likely to exacerbate practical barriers to screening for healthcare professionals. We therefore aimed to determine the prevalence and nature of screening barriers among staff at University Hospitals Bristol and Weston (UHBW) and whether on-site, staff-only cervical smear clinics could mitigate these barriers.
- 11 July 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (3) , e000185
Open AccessCervical screening programme accessibility for healthcare staff: ‘a call to action!’
The National Health Service (NHS) cervical screening programme has significantly reduced the incidence and mortality of cervical cancer. However, this vital service may not reach the whole eligible population. The national coverage remains below the 80% target, with only 68.7% of eligible people screened in 2023 in England. 1 Practical, psychological and socioeconomic barriers, alongside low perceived risk, continue to limit uptake.2–4 NHS statistics reported there were 1.16 million females employed in December 2024,5 the majority of whom are eligible for cervical screening. Shift work, rota inflexibility and staff shortages are likely to exacerbate practical barriers to screening for healthcare professionals. We therefore aimed to determine the prevalence and nature of screening barriers among staff at University Hospitals Bristol and Weston (UHBW) and whether on-site, staff-only cervical smear clinics could mitigate these barriers.